登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603538 证券简称：美诺华 转债代码：113618 转债简称：美诺转债 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 ■ (二)非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 ■ 二、股东信息 (一)普通股股东总数和表决权恢复的优先股股东数量及前十名股东持股情况表 单位：股 ■ 持股5%以上股东、前10名股东及前10名无限售流通股股东参与转融通业务出借股份情况 □适用 √不适用 对公司将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》未列举的项目认定为非 ...

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-056 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 第五届监事会第十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 宁波美诺华药业股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日以 书面、电子邮件等方式向公司全体监事发出召开第五届监事会第十四次会议的通 知和会议材料。2025 年 4 月 29 日，公司第五届监事会第十四次会议在公司会议 室以现场结合通讯表决方式召开。本次会议由刘斯斌先生主持，会议应出席监事 3 名，实际出席监事 3 名。公司董事会秘书应高峰先生列席会议。本次会议的召 集和召开符合《中华人民共和国公司法》等有关法律法规及《公司章程》《监事 会议事规则》的规定。 2025 年 4 月 30 日 报备文件： 监事会审核并发表如下意见：《2025 年第一季度报告》的编制和审核程序符 合法律、行政法规 ...

二、董事会会议审议情况 1、审议通过《2025 年第一季度报告》 | 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-055 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 第五届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 宁波美诺华药业股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日以 书面、电子邮件等方式向公司全体董事发出召开第五届董事会第十四次会议的通 知和会议材料。2025 年 4 月 29 日，公司第五届董事会第十四次会议在公司会议 室以现场结合通讯表决方式召开。本次会议由姚成志先生主持，会议应出席董事 5 名，实际出席董事 5 名。公司监事、高级管理人员列席了会议。本次会议的召 集和召开符合《中华人民共和国公司法》等有关法律法规及《公司章程》《董事 会议事规则》的规定。 具体内容详见公司于上海证券交易所网（www.sse.com.cn）等 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 276,483,125.97, representing a 5.22% increase compared to CNY 262,766,361.43 in the same period last year[3]. - Net profit attributable to shareholders increased by 51.12% to CNY 21,221,727.07 from CNY 14,043,259.71 year-on-year[3]. - Basic and diluted earnings per share rose by 42.86% to CNY 0.10 from CNY 0.07 in the previous year[3]. - The company reported a decrease of 19.02% in net profit attributable to shareholders after deducting non-recurring gains and losses, totaling CNY 16,622,403.34 compared to CNY 20,527,312.45 last year[3]. - Net profit for Q1 2025 was ¥23,190,551.99, representing a 47.0% increase from ¥15,770,884.38 in Q1 2024[17]. - Earnings per share for Q1 2025 were ¥0.10, compared to ¥0.07 in Q1 2024, indicating a growth of 42.9%[17]. Cash Flow and Liquidity - The net cash flow from operating activities improved to -CNY 25,479,750.86, a significant reduction from -CNY 54,422,979.34 in the same period last year[3]. - Cash inflow from operating activities for Q1 2025 was $366,592,076.69, an increase of 16.6% compared to $314,422,241.75 in Q1 2024[21]. - Net cash outflow from operating activities for Q1 2025 was -$25,479,750.86, an improvement from -$54,422,979.34 in Q1 2024[21]. - The net increase in cash and cash equivalents for Q1 2025 was $67,582,405.59, compared to a decrease of -$42,881,422.30 in Q1 2024[22]. - The ending balance of cash and cash equivalents for Q1 2025 was $380,530,147.67, a significant increase from $231,088,104.66 in Q1 2024[22]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,644,853,669.43, a slight decrease of 0.14% from CNY 4,651,221,247.28 at the end of the previous year[4]. - The total liabilities increased from RMB 1,080,000,000 to RMB 1,200,000,000, indicating a growth of approximately 11.1%[13]. - Short-term borrowings increased significantly from RMB 479,056,993.19 to RMB 659,176,824.56, representing a rise of about 37.5%[13]. - The total liabilities decreased slightly to ¥2,324,744,198.14 in Q1 2025 from ¥2,359,778,651.01 in Q1 2024[16]. - The total equity increased to ¥2,320,109,471.29 in Q1 2025, up from ¥2,291,442,596.27 in Q1 2024, showing a growth of 1.2%[16]. Expenses - Sales expenses surged by 61.50%, primarily due to the ongoing expansion of domestic business and increased share-based payment allocation[6]. - Financial expenses skyrocketed by 216.95%, attributed to the capitalization of interest expenses related to convertible bonds[6]. - Total operating costs for Q1 2025 were ¥258,654,126.54, up from ¥239,538,003.21 in Q1 2024, reflecting a year-over-year increase of 7.9%[16]. - Research and development expenses for Q1 2025 were ¥15,012,233.31, slightly down from ¥15,827,004.16 in Q1 2024[16]. Investments and Future Plans - The company reported an investment income of ¥3,061,477.94 in Q1 2025, a significant recovery from a loss of ¥13,589,352.18 in Q1 2024[16]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[19].

关于完成工商登记变更并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 宁波美诺华药业股份有限公司（以下简称"公司"）注册资本变更为 218,603,861 元，已完成相关工商登记变更，并取得换发后的《营业执照》。 2025 年 4 月 17 日，公司召开第五届董事会第十三次会议，审议通过了《关 于修订<公司章程>的议案》。《公司章程》修订后，公司注册资本为人民币 21,860.3861 万元，股份总数为 21,860.3861 万股。本次修订已分别取得 2021 年第四次临时股东大会及 2023 年年度股东大会授权，无需提交股东大会审议。 具体内容详见公司于 2021 年 12 月 7 日、2024 年 5 月 21 日、2025 年 4 月 18 日 在上海证券交易所网站（http://www.sse.com.cn/）及相关指定媒体披露的公告， 公告编号：2021-100，2024-046，2025-046。 2025 年 4 月 28 日，公司已完成相关工商登记变更，并取得宁波市市场监督 ...

宁波美诺华药业股份有限公司 2024 年年度股东大会会议资料 宁波美诺华药业股份有限公司 2024 年年度股东大会会议资料 中国·宁波 二○二五年五月八日 1 | 议案十三 49 | | --- | | | | 宁波美诺华药业股份有限公司 2024 年年度股东大会会议资料 会 议 议 程 一、会议时间、地点 召开时间：2025 年 5 月 8 日，14：00 召开地点：浙江省宁波市高新区扬帆路 999 弄研发园 B1 号楼 12A 层 1 号会议室 二、会议议程 1、会议主持人宣布大会开始，推选计票人、监票人各两名； 2、董事会秘书宣读大会会议须知； 3、会议主持人介绍会议议案： | 序 | | 议案名称 | 投票股东类型 | | --- | --- | --- | --- | | 号 | | | A 股股东 | | | | 非累积投票议案 | | | 1 | 《2024 | 年度董事会工作报告》 | √ | | 2 | 《2024 | 年度监事会工作报告》 | √ | | 3 | 《2024 | 年年度报告及摘要》 | √ | | 4 | 《2024 | 年度财务决算报告》 | √ | | 5 | 《202 ...

宁波美诺华药业股份有限公司"美诺转债"2025 年第一次债券持有人会议 会议资料 宁波美诺华药业股份有限公司 "美诺转债"2025 年第一次 债券持有人会议 会议资料 1 | 关于变更部分募集资金投资项目的议案 5 | | --- | 宁波美诺华药业股份有限公司"美诺转债"2025 年第一次债券持有人会议 会议资 会 议 议 程 中国·宁波 二○二五年五月八日 目录 会 议 议 程..................................................................................................... 3 B1 号楼 12A 层 1 号会议室 3 料 一、会议基本情况 1、现场会议时间：2025 年 5 月 8 日，12:00 2、现场会议地点：浙江省宁波市高新区扬帆路 999 弄研发园 3、会议表决方式：采用记名方式现场投票表决或通讯方式投票表决 二、会议主要议程 1、大会主持人宣布会议开始，介绍本次债券持有人会议现场会议的出席情况 2、推选现场会议监票人和计票人 3、宣读并逐项审议以下议案： （1）《关于变更部分募集资金投资项 ...

Group 1: Tianrongxin - Tianrongxin's sales of intelligent computing integrated machines exceeded 2 million units in Q1 2025, with orders surpassing 20 million, and annual sales expected to exceed 100 million [1] - The intelligent computing integrated machine is based on self-developed cloud computing products, providing a complete platform for intelligent applications, with prices ranging from hundreds of thousands to two million [1] - There is significant growth in demand for security in various sectors, including information security, cloud security, industrial internet security, and vehicle networking [1] - The company has partnered with insurance companies to launch various cybersecurity insurance products, with a business model that includes pre-assessment and post-service [1] - Downstream demand is expected to remain stable in Q1 2024, with high-quality orders remaining steady, indicating positive future business opportunities [1] - Revenue from government sectors is projected to decline in 2024 due to macroeconomic impacts and low-margin project reductions, but stable growth is expected in 2025 [1] - Supply chain impacts are currently minimal, but uncertainties may arise in the future, and the company has prepared in advance [1] - After years of intense competition, some manufacturers are beginning to weaken, which may improve industry competition [1] - AI applications are expanding security boundaries, increasing security demand, and enhancing customer security spending [1] - The workforce is expected to remain stable in 2025, with over 2,000 R&D personnel and a slight increase in sales staff [1] - No goodwill impairment is expected in 2025, while 2023's impairment was due to specific circumstances [1] Group 2: Meinuohua - Meinuohua is in a growth and profit recovery phase for 2024, with overall operations showing steady growth, particularly in the finished drug sector [2] - The raw material sector has achieved market share breakthroughs with multiple new products, while the CDMO sector is progressing smoothly despite international macroeconomic impacts [2] - The company is actively embracing innovation and plans to make it a key strategic focus for future development [2] - Projected revenue for 2024 is 1.373 billion, representing a year-on-year increase of 12.85%, with API business growth at 6.1% and self-operated business growth at 83.52% [2] - TianKang Pharmaceutical's revenue increased by 51%, and the net profit attributable to the parent company reached 66.81 million, up 476.64% year-on-year [2] - Overall gross margin is 32.61%, an increase of 1.74% compared to 2023 [2]

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-053 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于召开2024年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2025 年 04 月 22 日（星期二）至 04 月 28 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过宁波美诺华药业股 份有限公司（以下简称"公司"）邮箱 nbmnh@menovopharm.com 进行提问。公司 将在说明会上对投资者普遍关注的问题进行回答。 宁波美诺华药业股份有限公司（以下简称"公司"）已于 2025 年 4 月 18 日发布公司 2024 年年度报告，为便于 ...

Core Viewpoint - Ningbo Meinuo Pharmaceutical Co., Ltd. reported a significant increase in revenue and net profit for the year 2024, driven by its integrated strategy in the pharmaceutical sector and strong performance in its formulation business [1][2]. Group 1: Financial Performance - The company achieved an operating income of 1.373 billion yuan, representing a year-on-year growth of 12.85% [1]. - The net profit attributable to shareholders reached 66.81 million yuan, marking a substantial increase of 476.64% compared to the previous year [1]. Group 2: Business Strategy and Market Position - Meinuo has focused on building robust partnerships with multinational pharmaceutical companies, leveraging its experience with European clients to enhance its business model [1]. - In 2024, overseas business accounted for 69.77% of total revenue, with European business making up 81.88% of the overseas segment [1]. - The formulation business saw a remarkable revenue increase of 83.52%, becoming the core driver of the company's revenue growth [1][2]. Group 3: Research and Development Focus - The company concentrated its R&D efforts on chronic disease treatment, aiming to overcome technical and patent barriers [2]. - Meinuo has developed multiple technology platforms, including sustained-release and solubility enhancement technologies, to create high-value products with significant market potential [2]. Group 4: Market Strategy - The company adopts a market strategy primarily focused on centralized procurement, while also exploring new channels such as grassroots medical markets, retail pharmacies, and e-commerce platforms [2]. - In 2024, several products, including Perindopril and Moxifloxacin tablets, successfully won bids in multiple provinces [2]. Group 5: Raw Material Business - Despite facing challenges such as rising raw material costs, the raw material business still achieved a revenue growth of 6.10% [2]. Group 6: Industry Insights - Industry experts highlight Meinuo's advantages in raw material quality and scale, which contribute to effective cost control and quality management in the formulation sector [3]. - The company's participation in centralized procurement has expanded its market coverage and increased its market share, leading to stable revenue growth [3].